KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Non-Current Assets (2017 - 2025)

Novartis Ag's Non-Current Assets history spans 9 years, with the latest figure at $80.5 billion for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 10.96% year-over-year to $80.5 billion; the TTM value through Dec 2025 reached $80.5 billion, up 10.96%, while the annual FY2025 figure was $80.5 billion, 10.96% up from the prior year.
  • Non-Current Assets for Q4 2025 was $80.5 billion at Novartis Ag, up from $72.5 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $86.1 billion in Q4 2021 and bottomed at $69.5 billion in Q4 2023.
  • The 5-year median for Non-Current Assets is $80.5 billion (2025), against an average of $77.8 billion.
  • The largest annual shift saw Non-Current Assets decreased 13.76% in 2023 before it grew 10.96% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $86.1 billion in 2021, then fell by 6.43% to $80.5 billion in 2022, then fell by 13.76% to $69.5 billion in 2023, then grew by 4.43% to $72.5 billion in 2024, then increased by 10.96% to $80.5 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Non-Current Assets are $80.5 billion (Q4 2025), $72.5 billion (Q4 2024), and $69.5 billion (Q4 2023).